Navigation Links
Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
Date:6/12/2008

bo (p<0.001), compared to all patients in the study receiving RG2417 who had an average improvement on MADRS of 3.0 points over placebo (p=0.01) as previously reported. This result may reflect the difficulty in accurately diagnosing bipolar disorder in the absence of frequent symptomatology and will be used in the design and execution of the next study.

"The safety and efficacy results of our previous study of RG2417 strongly support further evaluation in patients with bipolar disorder," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "We are very pleased to have someone with Gary's expertise to lead the next phase of our clinical development program."

The previously reported Phase 2a study was a multi-center study in which 83 patients received either RG2417 or a placebo twice a day for six-weeks. Patients in the RG2417 and placebo groups were well matched in their symptoms at baseline with the exception of mania for which the RG2417 group mania score was significantly higher (p=0.01). The objective of the study was to assess the safety and efficacy of RG2417 on the symptoms of bipolar depression as measured by the co-primary endpoints, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression of Change in Bipolar Disorder scale (CGI-BP-C). Patients were evaluated at baseline and then weekly using these standardized tools to assess change in their symptoms. Over the six-week treatment period, the study demonstrated a statistically significant improvement in the symptoms of depression in the patients receiving RG2417 when compared to placebo on the MADRS (p=0.01) and on the CGI-BP-C (p=0.044).

A complete review of the data suggests that RG2417 was well tolerated. This study was conducted under a development agreement with the Stanley Medical Research Institute, the largest nonprofit provider of funding for research on schizophrenia and bipolar disorder in the United States. <
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
3. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), ... Technology (Tray-style, Manifold, & Rotary) & Geography - ... MarketsandMarkets, defines and segments the lyophilization market on ... with analyses and projections of the market size ...
(Date:9/19/2014)... Fla. , Sept. 19, 2014  The body ... with the publication of two papers this past week.  ... – Head and Neck Surgery , finds that ... and subjective measures of sleep disordered breathing, leading the ... reduction in obstructive sleep apnea severity and improvement of ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. , Sept. 19, ... (PGDx), a provider of advanced cancer genome analysis ... a leader in discovering and developing highly selective ... the first-ever comprehensive genomic study of malignant mixed ... of the female reproductive system, also known as ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... Medical, Inc., the wholly-owned operating subsidiary of Patient ... the recently released 2011-2012 U.S. News and World ... of the SurgiCount Safety-Sponge® System, a clinically proven ... common surgical errors, retained surgical sponges.  Only 17 ...
... A new policy recommendation released on 20 July by ... of serological (blood) tests to diagnose active tuberculosis (TB). ... are different to QuantiFERON, which measures responses of white ... Active tuberculosis occurs when the TB organism has overcome ...
Cached Medicine Technology:SurgiCount Medical Announces Expanded Honor Roll Hospital Users, Landmark Product Usage Milestones Achieved 2SurgiCount Medical Announces Expanded Honor Roll Hospital Users, Landmark Product Usage Milestones Achieved 3Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 2Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 3Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 4
(Date:9/19/2014)... Hastings and Hastings, a discount accident lawyer in Phoenix, ... record number of visitors to its new Phoenix personal injury ... cases as well as auto accident cases and slip & ... and others. Having served the state of Arizona for over ... time when it comes to dedicated and focused personal injury ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Boston Scientific ... mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled ... month, Bernstein Liebhard LLP reports. According to ... Court, the company asserts that claims involving its Solyx ... Practice and Remedies Code, a section of which shields ...
(Date:9/19/2014)... (HealthDay News) -- Although there is mounting evidence ... middle-aged and older adults in the United States ... to new research. Less than one-quarter of ... by the Department of Health and Human Services, ... for promoting health and fitness and staying independent, ...
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... statin medication caused some patients to develop Type 2 ... litigation now underway in U.S. District Court, District of ... Status Report issued on September 12, 2014, discovery is ... things, the report noted that Pfizer, Inc., the manufacturer ...
(Date:9/19/2014)... In partnership with Raw Beauty NYC, OC healthcare agency ... social media efforts. StudioPMG is honored to be a part ... beauty as it applies to disabled women. , The ... and Vanessa Silberman, who wanted to create a photo exhibit ... Wendy Crawford, Susan Solman and Sabrina Cohen later joined in ...
Breaking Medicine News(10 mins):Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2
... in soy foods such as tufu, soy milk or soy ... , ,However, the soy foods should be made from raw ... this, soy-supplemented muffins, cereals or nutritional bars do not offer ... prepare these foods. ,Beneficial soy products include soy ...
... that resveratrol, a compound found in grapes and ... peptides, which cause the telltale senile plaques of ... antioxidant compounds with potential neuroprotective activities. Resveratrol is ... widely studied for their health benefits. It is ...
... New bird flu vaccine is to be developed from this ... from wild birds which has killed wild and migratory poultry ... Organization (WHO). //WHO has given orders to the Wildlife Conservation ... very helpful during a possible attack. The WCS team of ...
... fact that one third of our lifetime is spent in sleep. ... quantity. A new study conducted reveals the lack of adequate sleep ... And the mail villain held responsible- Of course stress! ... 1003 adults by the Gallup Organization for International Longevity Center-USA to ...
... aging molecule, Klotho named after the Greek God who spins ... believed to play a very important role in the aging ... symptoms of aging, while over expression is associated with an ... the blood. The working mechanism however remained unclear. A ...
... sounded against bird flu at the Kaziranga National Park in ... sanctuary around this time every year. // ,Wildlife staff ... park have been alerted about the possibility of migratory birds ... immediately if any unusual avian behaviour. A veterinary doctor has ...
Cached Medicine News:Health News:Lack of adequate sleep among people over 50 2
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: